A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma (NCT06091254)
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 X Anti-CD3 Bispecific Antibody Versus Investigator's Choice in Previously Untreated Participants With Follicular Lymphoma (OLYMPIA-1)
🩺 Plain-English Summary (8th-Grade Level)
This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma (a type of non-Hodgkin lymphoma or NHL). This study will be made up of two parts: Part 1 (non-randomized) and Part 2 (randomized - controlled). The aim of Part 1 of the study is to see how safe and tolerable the study drug is when given alone. The aim of Part 2 of the study is to see how the study drug works compared to rituximab (called the "comparator drug") and chemotherapy (the current standard of care for NHL). Standard of care means the usual medication expected and used when receiving treatment for a condition. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects) * How the study drug affects quality of life and ability to complete routine daily activities.
Who can join: Review the eligibility criteria below.
Location: University of Arizona Cancer Center — Tucson, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (190 Sites)
Showing the first 25 of 190 sites.
- University of Arizona Cancer Center — Tucson, Arizona
- David Geffen School of Medicine at UCLA — Los Angeles, California
- UC Irvine Health — Orange, California
- Investigative Clinical Research of Indiana — Noblesville, Indiana
- Beth Israel Deaconess Medical Center — Boston, Massachusetts
- Karmanos Cancer Institute — Detroit, Michigan
- Hattiesburg Clinic — Hattiesburg, Mississippi
- Icahn School of Medicine at Mt Sinai — New York, New York
- Stony Brook University Hospital — Stony Brook, New York
- Clinical Research Alliance Inc — Westbury, New York
- University of North Carolina — Chapel Hill, North Carolina
- Levine Cancer Institute — Charlotte, North Carolina
- University Hospitals Cleveland Medical Center — Cleveland, Ohio
- Vanderbilt University Medical Center — Nashville, Tennessee
- Center for Oncology and Blood Disorders — Houston, Texas
- HOPE Cancer Center of East Texas — Tyler, Texas
- Huntsman Cancer Institute - Oncology Division — Salt Lake City, Utah
- University of Virginia — Charlottesville, Virginia
- Virginia Commonwealth University — Richmond, Virginia
- Prohealth Care Inc — Waukesha, Wisconsin
- Ingham Institute — Liverpool, New South Wales
- Icon Cancer Centre - Wesley — Auchenflower, Queensland
- Flinders Medical Centre — Bedford Park, South Australia
- Monash Health — Clayton, Victoria
- Epworth Freemasons — East Melbourne, Victoria
📞 Contact the Study Coordinator
Phone: (844) 734-6643
Email: clinicaltrials@regeneron.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Follicular Lymphoma (FL)
- A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma — Camperdown, New South Wales
- Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma — Fresno, California
- A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma — Plantation, Florida
- Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma — Tucson, Arizona
Explore by condition: All Follicular Lymphoma (FL) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.